I'm not sure how Willis could have met the sales target.
BUB's overall reported revenue in FY22 was $104.2M.
Infant formula sales was 60% of group revenue, so about $62.5M in total.
China sales were 47% of group revenue, which is $49M in total.
Not sure exactly how the sales Willis are responsible for get counted, but one would think they would be primarily China sales of infant formula. Based on those figures above, they would have to be responsible for at least 80% of all IF sales BUB made in FY22, which seems highly unlikely...
Ann: Becoming a substantial holder, page-53
Add BUB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.0¢ |
Change
-0.005(4.00%) |
Mkt cap ! $107.1M | |||
| Open | High | Low | Value | Volume |
| 12.0¢ | 12.5¢ | 11.5¢ | $123.7K | 1.029M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 384896 | 12.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 966651 | 17 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| BUB (ASX) Chart |